Kornimate/medical-research-clean huggingface dataset:
philips airflosser study

Conditions: Gingivitis

Summary: in the current study, sonicare airfloss (af) will be used in combination with a manual toothbrush (mtb) in a population of manual toothbrush users who are irregular flossers and who exhibit signs of moderate gingivitis. the alternate test arm will be allocated to a no intervention group and will be given no test products or instruction other than to change none of their typical at home oral hygiene habits. the aim of this study is to investigate how an af and mtb oral hygiene intervention will affect a population of irregular flossers using the residual protein concentration method as an interproximal plaque efficacy assessment. gingivitis reduction will be assessed using the modified gingival index (mgi) and gingival bleeding index (gbi) indices


Eligibility criteria:
4.1 inclusion criteria subjects accepted into the study must meet the following requirements: * are 18-70 years; * are in generally good health; * have a minimum of 20 natural teeth (excluding 3rd molars); * have 1 qualifying test site in each posterior quadrant; * are a regular manual toothbrush user (prior periodic use of powered toothbrushes in other studies permitted); * irregular flossers defined as using dental floss ≤ 2 days a week; * be willing and able to comply with study procedures and be available at all times required for participation; * have a gingival bleeding index \> 1 on at least 20 sites; * be a non-smoker. 4.2 exclusion criteria subjects will be excluded from the study if they; * have systemic diseases such as down's syndrome, or known aids/hiv; * have insulin dependent diabetes; * are pregnant or nursing by subject report; * have a cardiac pacemaker or aicd; * are undergoing or require extensive dental or orthodontic treatment; * require antibiotic treatment for dental appointments; * have used antibiotics within 4 weeks of enrollment; * are currently using prescription-dose anti-inflammatory medications or anticoagulants (including aspirin); * have heavy deposits of calculus, either supragingival and/or subgingival; * have severe gingivitis or periodontitis; * have extensive crown or bridge work and/or rampant decay; * are currently use bleaching trays; * have any oral or extraoral piercing on lips or in mouth with ornament or accessory; * have a professional prophylaxis within 4 weeks of study; * have participated in a prior study ≤ 20 days; * are employed by an oral healthcare products company or dental research institution.

Keywords: moderate gingivitis
efficacy and safety of tocilizumab in the treatment of generalized myasthenia gravis

Conditions: Myasthenia Gravis, Generalized

Summary: randomized, double-blind, placebo-controlled, parallel-group study with optional open-label extension.

this study is a randomized, double-blind, placebo-controlled study, to be conducted at 6 study sites. approximately 64 subjects will be enrolled. patients with mg who are positive for anti-achr antibodies will be enrolled. patients who do not have anti-achr or anti-musk antibodies will not be enrolled. patients with mgfa classification ii, iii, or iv disease, mg-adl score ≥ 5, qmg score ≥ 11, and use of a corticosteroid and/or non-steroidal immunosuppressant will be included in the study. all subjects who complete the randomized controlled period will have the option to enroll in a 1-year open-label period.

Eligibility criteria:
inclusion criteria: 1. diagnosis of mg with anti-achrantibody. 2. mgfa clinical classification class ii, iii, or iv. 3. mg-adl score of 5 or greater at screening and at randomization with \> 50% of this score attributed to non-ocular items. 4. qmg score of 11 or greater. 5. subjects must be on: 1. cholinesterase inhibitor, with no dose increase within 4 weeks prior to randomization; 2. corticosteroids, with no dose increase within 4 weeks prior to randomization; or/and c. non-steroidal ist (including azathioprine, mycophenolate mofetil, tacrolimus, cyclosporine a), with continuous use for at least 6 months prior to randomization and no dose increase within 4 months prior to randomization. exclusion criteria: 1. participants had clinically relevant active infections (such as sepsis, pneumonia, or abscess) or severe infections (resulting in hospitalization or requiring antibiotic treatment) in the 4 weeks before randomization; 2. those with a history of high-risk tuberculosis infection, acquired tuberculosis infection, and chronic hepatitis; 3. human immunodeficiency virus (hiv) infection; 4. thymomas that have received thymectomy or planned thymectomy during rcp within 6 months before randomization, or require chemotherapy and/or radiotherapy at any time; 5. received rituximab treatment in the past 6 months before randomization; 6. received tocilizumab or eculizumab treatment within 3 months before randomization; 7. received ivig or plasma exchange within 4 weeks before randomization; 8. unresected thymoma. 9. history of other tumor diseases.

Keywords: generalized myasthenia gravis tocilizumab
effectiveness of a standardized stroke upper limb rehabilitation program with shortened fugl-meyer assessment stratification

Conditions: Stroke

Summary: the objective of the study was to investigate the effectiveness of a standardized stroke upper limb rehabilitation program with stratification using shortened fugl-meyer assessment (s-fm). the standardized program was compared with conventional training based on the hospital protocol.


Eligibility criteria:
inclusion criteria: * first stroke, able to attend gym training and give written consent exclusion criteria: * unstable medical condition, any musculoskeletal conditions or other diseases restricted upper limb training, unfit mental state and unable to follow command

Keywords: shortened fugl-meyer assessment stroke rehabilitation upper limb
plexin b2 gene expression and polymorphisms in psoriasis

Conditions: Psoriasis Vulgaris

Summary: patients will be randomly assigned (1:1:1 ) either to ; nb-uvb photo-therapy alone , acitretin therapy alone or nb-uvb photo-therapy combined with acitretin therapy randomization will be done by closed envelopes . investigator will be blinded to study drug assignment , while patients and data interpreter will not be masked to study drug assignment.

study setting: qena university hospital, department of dermatology ,venereology\& andrology. study subjects: the study will include psoriasis vulgaris patients who come to the out patients dermatologic clinic and matching inclusion \& exclusion criteria as follow, from 9/2021 up to 3/2023 and then patients will be divided to each group equally as follow: group 1: patients will be treated with nb-uvb phototherapy 3 sessions weekly for 3 months with maximum dose of 1400 mj/cm2. group 2: patients will be treated with acitretin in dose of 0.5-1 mg per kg per day orally for 3 months group 3: patients will be treated with acitretin in dose of 0.5-1 mg per kg per day orally plus nb-uvb phototherapy 3 sessions weekly for 3 months with maximum dose 1400 mj/cm2. group 4: 30 healthy individuals un related , age, sex , bmi matched with volunteers.

Eligibility criteria:
inclusion criteria: * patients of both sexes. diagnosed clinically with moderate to severe psoriasis vulgaris. * patients able to swallow tablet and receive narrow band ultraviolet b phototherapy without any contraindication exclusion criteria: pregnancy , lactation \& women intent to become pregnant within 3 year after discontinuation of acitretin patients with hyperlipidemia patients with mental problems and depression patients with a history of malignancies, renal \& liver diseases. patients with a history of any inflammatory diseases as atopic dermatitis , asthma ulcerative colitis ) and crohn's disease patients received nb-uvb phototherapy in the last 6 months. patients treated with methotrexate or biologic agents and any systemic treatment of psoriasis.
intracavitary carrier-embedded cs131 brachytherapy for recurrent brain metastases: a randomized phase ii study

Conditions: Recurrent Brain Metastases

Summary: the purpose of this study is to see if cs-131 brachytherapy is effective in people with recurrent brain cancer who are scheduled to have brain surgery for removal of their tumor(s). the researchers would like to see whether cs-131 prevents brain tumors from growing back after surgery.the researchers will compare cs-131 brachytherapy (which occurs during brain surgery) with the usual approach of brain surgery without brachytherapy. the researchers will compare both the effectiveness and safety of the two approaches.


Eligibility criteria:
inclusion criteria: * adult patients ≥ 18 years of age who are capable of giving consent * undergoing elective craniotomy for resection of a previously-irradiated brain metastasis with suspicion for viable disease at the time of consent, and anticipated achievement of gross-total or near-total (\>/=95%) resection * karnofsky performance status score (kps) of ≥70 * ability to undergo brain mri with gadolinium exclusion criteria: * unable to tolerate mri or ct imaging * pregnancy (patients must have a negative pregnancy test within 30 days of the operation) * women must agree to not breastfeed for at least 12 weeks after the procedure (lactating and discarding in that interval allowable) * diagnosis of leptomeningeal carcinomatosis or \>5 additional active or untreated cns lesions for a total of \>6 active lesions * prior irradiation (eqd2) in excess of 100 gy to site of implant, using an α/β of 2 * apposition of tumor margin to brainstem or optic apparatus * previous infection within the operative field, current active systemic infection requiring systemic therapy, or immunodeficiency * urgent surgery required prior to availability of brachytherapy intraoperative exclusion criterion: * patients will be excluded if intraoperative pathology is not consistent with \>/=5% viable metastatic disease.

Keywords: cs-131 brachytherapy brain metastasis 20-542
evaluation of the performance of a new rapid bacteremia test in the intensive care patient

Conditions: Sepsis

Summary: sepsis is a serious health problem with a very high mortality in the icu. the most important treatment for sepsis is the fastest possible antibiotic therapy. the identification of the pathogen responsible for sepsis is essential to propose an appropriate antibiotic treatment. however, the diagnosis of bacteremia by blood culture requires an average delay of 48 to 72 hours. the new test proposed by ocean dx makes it possible to identify a bacteremia in a few hours. the main objective of the study is to evaluate the performance of the rapid identification test for bacteremia proposed by ocean dx compared to a classic diagnostic strategy using blood cultures.

sepsis is a worldwide problem. the world health organization estimates that around 49 million people suffer from sepsis each year. it is responsible for an unacceptable number of deaths, estimated at around 11 million. the severity of sepsis is not only related to the infection itself, but often to a too late diagnosis and an important heterogeneity in the management of patients. the identification of the pathogen responsible for sepsis is currently based on the positivity of bacteriological samples, particularly blood cultures. however, the diagnosis of bacteremia by blood cultures requires an average delay of 48 to 72 hours, which is not conducive to rapid adaptation of antibiotic therapy. the test proposed by ocean dx offers the identification of a bacteremia in a few hours thanks to the recognition of the bacterial dna in the patient's blood. the main objective of the study is to evaluate the performance of the rapid identification test for bacteremia offered by ocean dx in comparison with a classical diagnostic strategy using blood cultures.

Eligibility criteria:
inclusion criteria: * patients over 18 years of age admitted to an intensive care unit (icu) with a suspected or documented infection requiring blood cultures. exclusion criteria: * patient under 18 years of age * pregnant or breastfeeding woman * patient of legal age, under guardianship or deprived of liberty * not affiliated to a social security regime or not benefiting from such a regime.

Keywords: intensive care blood culture bacteremia rapid diagnostic tests antimicrobial resistance
pursestring wound closure vs "gunsight" skin incision and closure technique to reverse stoma

Conditions: Colostomy

Summary: the use of temporary stomas has been demonstrated to reduce septic complications after colorectal cancer surgery, especially in high-risk anastomosis; therefore, it is necessary to reduce the number of complications secondary to ostomy takedowns, namely wound infection. the aim of this study is to compare the rates of superficial wound infection, healing time and patient satisfaction after pursestring closure vs "gunsight" skin incision and closure technique closure.


Eligibility criteria:
inclusion criteria: * loop colostomy * end colostomy exclusion criteria: * other stomy

Keywords: reversal surgical technique pursestring wound closure gunsight skin incision and closure technique
can you reduce problematic smartphone use through a group intervention: a single case experimental design

Conditions: Addiction, Smartphone

Summary: this study will develop and conduct an initial, single-case, mixed-methods evaluation of a brief group intervention for mild and moderate problematic phone use.


Eligibility criteria:
inclusion criteria: -self-identifies as struggling with problematic smart phone use exclusion criteria: * actively experiencing suicidal or self-injurious thoughts, or have experienced these within the past year * already in a psychological therapy/intervention * planning a change of psychotropic medication during the research project. * no access to video calling and/or slow internet connection speed * a mental health condition that is not currently well managed/stable and therefore other interventions are likely to be more appropriate * does not own a smartphone that can record screen time * is not living in the uk, with access to services within the uk
to assess the accuracy and reliability of the ga68-dolacga positron emission tomography compared to computer tomography volumetry and indocyanine green retention test for measurement of liver reserve

Conditions: Hepatic Carcinoma

Summary: this is a phase 2 open-labeled study to compare the ga68-dolacga positron emission tomography with computer tomography volumetry and indocyanine green retention test for measurement of liver reserve among scheduled surgery operation patients.

this is a phase 2 open-labeled study to compare the ga68-dolacga positron emission tomography with computer tomography volumetry (ctv) and indocyanine green retention test (icgr15) for measurement of liver reserve among scheduled surgery operation patients. the goal is to enroll 30 eligible subjects scheduled for surgery operation. ctv and icgr15 will occur within 7 days prior to the imaging visit for all eligible subjects. during the imaging visit (visit 2, day 1), subjects will receive an iv bolus injection of 2.0±1.0 mci ga68-dolacga injection. ga68-dolacga pet will be kinetically performed 60 minutes immediately after iv injection. two follow-up visits (visit 3 at day 7±2 and visit 4 at day 14±2) will be conducted to confirm subject well-being and to collect information about any new adverse events (if any).

Eligibility criteria:
inclusion criteria: 1. scheduled operation subjects with diagnosed hepatic carcinoma. the eligibility criteria for operation refer to protocol appendix ii: diagnosis and treatment guidelines for hepatocellular carcinoma in chang gung memorial hospital; 2. subjects without ascites or with controllable ascites; 3. serum total bilirubin level \< 2.0 mg/dl; 4. written informed consent must be obtained before any assessment is performed. 5. male or female subjects aged 20 or above, inclusive, at date of consent. exclusion criteria: 1. presence of distant metastases; 2. a body weight loss of \>10% during the 6 months before operation; 3. presence of seriously impaired function of vital organs due to respiratory, renal, or heart disease; 4. cholangiocarcinoma; 5. general pet exclusion criteria; 6. pregnant women, lactating or breast-feeding women; 7. patient who can't be followed up for any reason.
infergen and ribavirin treatment of patients with hcv who achieved partial response to peginterferon-alfa and ribavirin

Conditions: Hepatitis C

Summary: this is a 60-to-72 week multicenter study to evaluate infergen and ribavirin in patients with chronic hepatitis c virus after partial response to treatment using peginterferon-alfa and ribavirin therapy. the study will be conducted at approximately 50 sites across the united states.


Eligibility criteria:
inclusion criteria: * male or female, at least 18 years of age and no older than 65 years with compensated chronic hcv infection based on a history of positive serum anti-hcv antibody and/or hcv rna * diagnosed with hcv genotype 1, 4, 5 or 6 as determined during the screening visit * the starting doses in the initial treatment must have been 1.5 μg/kg/week peg-intron or 180 μg/week pegasys, and 1000/1200 mg/day ribavirin based on body weight. patients must have been at least 80% compliant during the initial peginterferon/ribavirin therapy, per patient account. * liver biopsy indicating f0-f4 must be performed within 3 years prior to screening. documentation of the results of the biopsy must be available. if documentation is not available, a liver biopsy must be performed during the screening period. (a maximum of 10 patients in each of the three treatment groups will be patients with a fibrosis score of f4) * documented partial response after 12 weeks of treatment as a therapy-naive patient with one course of peginterferon alfa-2a (pegasys) and ribavirin or peginterferon alfa-2b (peg-intron) and ribavirin exclusion criteria: * detectable hcv rna after 12 weeks if initial peginterferon alfa/ribavirin therapy and \<2 log decrease in hcv rna at week 12 from baseline. * hcv genotype 2 or 3 * severe neuropsychiatric disorder. * history or clinical manifestations of significant metabolic, hematological, pulmonary, ischemic heart disease, significant or unstable heart disease, gastrointestinal, neurological, renal, urological, endocrine, ophthalmologic disorders including severe retinopathy, or immune-mediated disease. * known hiv infection or positive hiv at screening. * pregnant or breast-feeding patients. * underlying autoimmune disease

Keywords: chronic hepatitis c liver pegylated interferon ribavirin combination nonresponder relapser hcv infergen svr
effect of remote ischemic post-conditioning on out-of-hospital cardiac arrest

Conditions: Out-Of-Hospital Cardiac Arrest

Summary: ischemia-reperfusion leads to mitochondrial injury, ion-pump injury, cell membrane damage, cytotoxic edema, and excessive oxygen free radical formation, and eventually destroys cells. cardiac arrest is an example of global ischemia; after spontaneous circulation is restored, ischemia-reperfusion injury develops in cardiac arrest survivors. remote ischemic postconditioning (ripoc) involves the application of brief, reversible episodes of ischemia and reperfusion to a vascular bed or tissue, rendering remote tissues and organs resistant to ischemia-reperfusion injury. accordingly, ripoc has been suggested as adjunctive therapy to mitigate ischemia-reperfusion injury. ripoc applied by repeated brief inflation-deflation of a blood pressure cuff protects against myocardial injury, and has been proven effective in acute myocardial infarction. this study aims to perform a randomized controlled trial to determine whether ripoc has a neuroprotective effect and aids in myocardial recovery in out-of-hospital cardiac arrest patients after restoration of spontaneous circulation. neuron-specific enolase (nse) at 48 hours after restoration of spontaneous circulation will be measured as a primary outcome.


Eligibility criteria:
inclusion criteria: * adult (19 years and older) * comatose out-of-hospital cardiac arrest with sustained restoration of spontaneous circulation * undergoing targeted temperature management * time of enrollment ≤ 6hrs from restoration of spontaneous circulation * cardiac arrest from medical cause (cardiac or other medical cause) exclusion criteria: * pre-existing dementia, brain injury, or dependence on others (cerebral performance category scale greater than 3) * traumatic etiology for cardiac arrest * protected population (pregnant, prisoner) * in-hospital cardiac arrest * known bleeding diathesis * suspected or confirmed acute intracranial hemorrhage * suspected or confirmed acute ischemic stroke * known limitations in therapy and do-not-resuscitate order * known disease making 180-day survival unlikely * \>6 hours from restoration of spontaneous circulation to randomization * cardiac arrest from asphyxia (hanging, foreign body airway obstruction), drowning, drug overdose, or electrocution * peripheral vascular disease (deep vein thrombosis, arteriosclerosis obliterans) * systolic blood pressure \< 80 mmhg in spite of fluid loading/vasopressor and/or inotropic medication
rsv observational study 2

Conditions: Respiratory Syncytial Virus Infections

Summary: respiratory syncytial virus (rsv) is a virus that causes chest infections. it is the single most important cause of severe respiratory illness in infants and young children, and severe rsv infection early in life is associated with an increased risk of later developing asthma. rsv also causes severe disease in elderly and immune-compromised adults, and the amount of rsv disease in the elderly is similar to that from seasonal flu. the virus is transmitted in the secretions of the upper respiratory tract of infected individuals and by contact with contaminated surfaces (such as toys). hospital outbreaks, especially on paediatric and neonatal wards, are not uncommon. infection by rsv does not develop a natural long-lasting protection against re-infection (like, for example, measles does). in the usa nearly all children by 24 months of age have been infected at least once with rsv, and about half will have experienced two infections. there is no effective anti-viral drug to treat an infection and the only way of managing cases of severe infection is through supporting organs, such as the lungs, to withstand and recover from the illness. there remains a real need to develop an effective vaccine to prevent severe infections caused by rsv. a better understanding of the way the immune system responds to rsv in children would aid the development of such a vaccine. the purpose of this study is to increase our understanding of how the immune system responds to rsv. only limited data is available on some important components of the immune response and this study is designed to measure these in more detail. this is done using a single blood sample. a total of 35 children are anticipated to be recruited to this study, at ages when we expect to see differences in the immune response to rsv; * 5 infants aged between 2 and 4 months (group 1), who have not yet been exposed to rsv * 20 infants aged between 6 and 12 months (group 2), who will have had exposure to one single rsv season in the winter of 2011/12 * 10 children aged between 3 and 6 years (group 3), who have been exposed to rsv over several winter seasons


Eligibility criteria:
inclusion criteria: * parent or guardian is willing and able to give informed consent for participation in the study * age suitable for group 1, 2 or 3 as defined in above (section 6.2) * delivery at 36 weeks gestation or later * having a blood sample for clinical reasons exclusion criteria: * parent or guardian unable or unwilling to give informed consent for participation in the study * any impaired function of the immune system, by medication or pathological process, which could augment or impair the immune response to rsv * concurrent acute or chronic infection * any chronic illness which, in the opinion of the investigator, may lead to incorrect or inaccurate immunology data * history of immunoprophylaxis with palivizumab * delivery prior to 36 weeks gestation

Keywords: rsv immune response paediatric